Literature DB >> 23334629

Tumefactive demyelination: an approach to diagnosis and management.

Todd A Hardy1, Jeremy Chataway.   

Abstract

Tumefactive lesions are an uncommon manifestation of demyelinating disease and can pose a diagnostic challenge in patients without a pre-existing diagnosis of multiple sclerosis. Choosing when to biopsy a tumefactive lesion to exclude alternative pathology can be difficult. Other questions include how best to treat an acute attack as well as the optimal timing of therapy to prevent relapse. This article aims to review the available literature for tumefactive demyelination and to propose an approach to diagnosis and management. We argue that disease modifying therapy should be considered for acute tumefactive demyelinating lesions only once criteria of dissemination in time and space are fulfilled and the diagnosis of multiple sclerosis is confirmed.

Entities:  

Keywords:  Multiple Sclerosis; Neuroimmunology; Neuropathology; Neuroradiology; Tumours

Mesh:

Year:  2013        PMID: 23334629     DOI: 10.1136/jnnp-2012-304498

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Authors:  Afsaneh Shirani; Gregory F Wu; Caterina Giannini; Anne H Cross
Journal:  BMJ Case Rep       Date:  2018-06-28

2.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

3.  Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis.

Authors:  Lucia Patriarca; Silvia Torlone; Fabiana Ferrari; Caterina Di Carmine; Rocco Totaro; Ernesto di Cesare; Alessandra Splendiani
Journal:  Neuroradiol J       Date:  2016-08-16

4.  Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Authors:  A Siri; Clarisse Carra-Dalliere; X Ayrignac; J Pelletier; B Audoin; S Pittion-Vouyovitch; M Debouverie; C Lionnet; F Viala; D Sablot; D Brassat; J-C Ouallet; A Ruet; B Brochet; L Taillandier; L Bauchet; N Derache; G Defer; P Cabre; J de Seze; C Lebrun Frenay; M Cohen; P Labauge
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

5.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

6.  Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Authors:  Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei
Journal:  Neurol Sci       Date:  2016-04-15       Impact factor: 3.307

7.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

8.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

9.  18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Authors:  Sied Kebir; Florian C Gaertner; Marcus Mueller; Michael Nelles; Matthias Simon; Niklas Schäfer; Moritz Stuplich; Christina Schaub; Michael Niessen; Frederic Mack; Ralph Bundschuh; Susanne Greschus; Markus Essler; Martin Glas; Ulrich Herrlinger
Journal:  Oncol Lett       Date:  2016-02-04       Impact factor: 2.967

Review 10.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.